SELL (from current proposed entry) / selective BUY at adjusted entry of $25.00-$25.50

• Entry price of $29.50 is $2.74 above current verified close of $26.76; proposed risk per share of $3.00 assumes an entry that doesn't exist
• TTM EPS of $0.76 versus forward EPS of $2.87 implies 3.8x recovery requiring flawless execution across ramp, cost program, and pipeline
• GAAP net margin of 6.8%, negative tangible book value of minus $38.5 billion, recurring $5-9 billion annual impairments undermine normalized earnings quality
• Q2 impairment of $4.325 billion is second consecutive quarter of major non-cash writedowns; management signaling overstated asset carrying values
• Q2 free cash flow of $302 million down sharply from Q4 2025's $4.5 billion; dividend coverage at 1.20x creates fragility
• Revenue declined from $101 billion peak in 2021 to $62.6 billion in 2025; 15% stock rally reflects multiple expansion, not earnings recovery
• Technical analysis explicitly calls for mean reversion to middle Bollinger Band at $24.91 before next leg higher, contradicting aggressive continuation thesis
• RSI >74 and price above upper Bollinger Band signal overbought conditions at current levels
• Starboard activism premium likely partially priced in already; embedded alpha decays within 6-9 months of public disclosure
• Berobenatide readout is binary risk in GLP-1 field where Lilly and Novo are entrenched; negative readout threatens pipeline narrative
• No Fed cuts regime removes multiple-expansion catalyst; yields at 6.56% with no rate tailwind create yield trap risk
• Conservative entry: pullback to $25.00-$25.50 where 10 EMA, 200 SMA, and VWMA converge; stop at $24.50 reduces risk to ~$2.26 per share
• Conservative position sizing: 2-3% versus aggressive 3-4%; adjust entry timing before committing firm capital

→ vs aggressive: Entry price of $29.50 is $2.74 above current market; proposed structure assumes non-existent entry price, not a real market level

→ vs aggressive: Forward P/E of 9.3x and fair value of $32-$37 assume 3.8x earnings recovery that is consensus projection, not confirmed earnings; TTM EPS is only $0.76

→ vs aggressive: GAAP net margin of 6.8%, negative tangible book value of minus $38.5 billion, and recurring $5-9 billion annual impairments contradict 'confirmed by every metric' claim

→ vs aggressive: Q2 impairment of $4.325 billion is 'accounting artifact' only if dismissing second consecutive quarter of major writedowns as noise

→ vs aggressive: Q2 free cash flow of $302 million versus Q4 2025's $4.5 billion is actual cash generation cratering, not a GAAP artifact

→ vs aggressive: Dividend coverage at 1.20x is thin; aggressive calls it a 'floor' but analyst calls it a fragile support level with limited margin for error

→ vs aggressive: Patent cliff dismissal based on 15% trailing rally is 'complete non-sequitur'; revenue fell from $101B to $62.6B while stock rallied on multiple expansion

→ vs aggressive: Technical analysis authors explicitly state RSI >74 and upper Bollinger Band breakout is mean-reversion setup, not continuation signal; aggressive contradicts source material

→ vs aggressive: Starboard activism argument is 'misplaced confidence'; activist premium likely already partially priced in with alpha decaying within 6-9 months

→ vs aggressive: Berobenatide binary event framed as 'paid to wait' ignores that negative readout in GLP-1 field creates credible dividend threat with coverage at 1.20x

→ vs aggressive: No Fed cuts regime removes multiple-expansion catalyst for defensive names; calling high yield with no rate tailwind a 'feature' is inverted logic

BUY with staged entry: buy-stop at $27.00-$27.20 (or buy-limit $25.50-$25.00 on pullback), stop at $25.50, size 3% initial (up to 4% on catalyst confirmation)

• Entry price of $29.50 is indefensible given stock closed at $26.76
• Staged entry: buy-stop at $27.00-$27.20 triggers on confirmed breakout above upper Bollinger Band; contingent buy-limit at $25.50-$25.00 if price pulls back
• Stop at $25.50 sits below 200 SMA, VWMA, and 50 SMA — clear structural invalidation, $1.50 risk (2.8 ATR) from $27.00 entry
• Position sizing: 3% starter, add to 4% max on berobenatide readout or clean Q3 confirmation
• Forward P/E of 9.3x vs TTM of 35.2x reflects depressed earnings trough; normalized EBITDA $25.7B on $62B revenue is cheap
• Non-COVID revenue growing 5% operationally; $2.5B incremental cost target is real; Starboard engagement is real
• $4.3B Q2 impairment is recurring pattern and management signal about asset values — not accounting noise
• Dividend coverage at 1.20x ($11.7B operating cash flow vs $9.8B dividends) is tight; 6.56% yield is support, not fortress
• Q2 free cash flow $302M against $2.45B dividends paid reveals quarterly cash flow strain
• RSI at 74.73 indicates overbought conditions; upper Bollinger Band breakout carries mean-reversion risk to $24.91 middle band
• MACD crossed bullish end of July and expanding; 200 SMA rising eight months; 50 SMA turning higher
• 62 million shares institutional volume confirms trend flip
• Macro backdrop is bidirectional: removes rate compression catalyst but reinforces defensive yield demand at 0.28 beta
• Thesis review at obesity readout, Q3 print, and macro-shift events; exit if operating cash flow deteriorates, not just GAAP optics

→ vs aggressive: Calls $4.3B Q2 impairment 'accounting noise' but impairment signals management's own internal model projects lower asset values — this is cash-relevant information about the forward earnings bridge

→ vs aggressive: Frames 6.56% dividend yield as a 'floor' and 'being paid to wait,' but 1.20x operating cash flow coverage and Q2 FCF of $302M vs $2.45B dividends paid is not a fortress — it's a meaningful yield support, not a dividend fortress

→ vs aggressive: Calls upper Bollinger Band breakout on volume a continuation signal, but RSI at 74.73 signals overbought conditions and technical report explicitly characterizes same setup as mean-reversion risk to $24.91 middle band

→ vs conservative: Patient $25.00-$25.50 entry target is a bet against momentum in a name that just broke out on 62M shares of institutional volume with MACD bullish cross, rising 50 SMA, and 200 SMA rising for eight months — waiting risks missing the move entirely given approaching catalyst calendar

→ vs conservative: Patent cliff and yield trap concerns are valid but the chart shows the market is not pricing those concerns in at current levels — that divergence is information, not noise to be ignored